The spleen tyrosine kinase (SYK): A crucial therapeutic target for diverse liver diseases

The spleen tyrosine kinase (SYK): A crucial therapeutic target for diverse liver diseases

Spleen tyrosine kinase (SYK) is an enigmatic protein tyrosine kinase, and involved in signal transduction related with lots of cellular processes. It’s highly expressed in the cells of hematopoietic origin and acts as an important therapeutic target in the treatment of autoimmune diseases and allerg...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Yaping Zhao, Rongrong Liu, Miaomiao Li, Pengfei Liu
Formato:	Artigo
Idioma:	English
Publicado em:	Elsevier 2022-12-01
Colecção:	Heliyon
Assuntos:	Spleen tyrosine kinase (SYK) Liver diseases Small molecule inhibitor Therapy target
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2405844022034181

Registos relacionados

The selective inhibition of the Syk tyrosine kinase ameliorates experimental autoimmune arthritis
Por: Eszter Káposztás, et al.
Publicado em: (2023-12-01)

Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib
Por: Nichola Cooper, et al.
Publicado em: (2023-01-01)

Biochemical characterization of spleen tyrosine kinase (SYK) isoforms in platelets
Por: Pankaj Kumar Singh, et al.
Publicado em: (2023-12-01)

Activation of spleen tyrosine kinase (SYK) contributes to neuronal pyroptosis and cognitive impairment in diabetic mice via the NLRP3/Caspase-1/GSDMD signaling pathway
Por: Chenglong Zhou, et al.
Publicado em: (2024-12-01)

Identification of high-performing antibodies for tyrosine-protein kinase SYK for use in Western Blot, immunoprecipitation and immunofluorescence [version 3; peer review: 2 approved]
Por: Carl Laflamme, et al.
Publicado em: (2024-06-01)

Hematopoietic or Osteoclast-Specific Deletion of Syk Leads to Increased Bone Mass in Experimental Mice
Por: Dániel Csete, et al.
Publicado em: (2019-04-01)

Spleen tyrosine kinase (SYK) signals are implicated in cardio-cerebrovascular diseases
Por: Mohan Li, et al.
Publicado em: (2023-05-01)

Spleen tyrosine kinase mediates the γδTCR signaling required for γδT cell commitment and γδT17 differentiation
Por: Ryunosuke Muro, et al.
Publicado em: (2023-01-01)

Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis
Por: Christopher W. Pohlmeyer, et al.
Publicado em: (2021-03-01)

Anti-microbial cetylpyridinium chloride suppresses mast cell function by targeting tyrosine phosphorylation of Syk kinase
Por: Bright Obeng, et al.
Publicado em: (2024-12-01)

Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Por: Kata P. Szilveszter, et al.
Publicado em: (2019-08-01)

S-Layer From Lactobacillus brevis Modulates Antigen-Presenting Cell Functions via the Mincle-Syk-Card9 Axis
Por: Mariano Prado Acosta, et al.
Publicado em: (2021-03-01)

A spleen tyrosine kinase inhibitor attenuates the proliferation and migration of vascular smooth muscle cells
Por: Hyang‑Hee Seo, et al.

Spleen Tyrosine Kinase Is a Critical Regulator of Neutrophil Responses to <italic toggle="yes">Candida</italic> Species
Por: Paige E. Negoro, et al.
Publicado em: (2020-06-01)

Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases
Por: Yaqi Zhou, et al.
Publicado em: (2023-07-01)

CCL4‐mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease
Por: Wenbin Gong, et al.
Publicado em: (2021-02-01)

Inhibition of Spleen Tyrosine Kinase Restores Glucocorticoid Sensitivity to Improve Steroid-Resistant Asthma
Por: Qian Liu, et al.
Publicado em: (2022-05-01)

Systematic analysis of spleen tyrosine kinase expression and its clinical outcomes in various cancers
Por: Akram I Alwithenani, et al.
Publicado em: (2020-01-01)

Phosphorylation of (Ser 291) in the linker insert of Syk negatively regulates ITAM signaling in platelets
Por: Carol Dangelmaier, et al.
Publicado em: (2024-12-01)

The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients
Por: Jing Wang, et al.
Publicado em: (2023-02-01)

Expression of variant isoforms of the tyrosine kinase SYK differentially regulates cervical cancer progression through PI3K/AKT pathway
Por: Bingjie Lin, et al.
Publicado em: (2024-11-01)

Three Novel Players: PTK2B, SYK, and TNFRSF21 Were Identified to Be Involved in the Regulation of Bovine Mastitis Susceptibility via GWAS and Post-transcriptional Analysis
Por: Fan Yang, et al.
Publicado em: (2019-08-01)

Development of SYK NanoBRET cellular target engagement assays for gain–of–function variants
Por: Jacob L. Capener, et al.
Publicado em: (2024-07-01)

Effects of a spleen tyrosine kinase inhibitor on progression of the lupus nephritis in mice
Por: Maki Kitai, et al.
Publicado em: (2017-05-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
Por: Yi-fan Chen, et al.
Publicado em: (2011-12-01)

Tyrosine kinase targeting: A potential therapeutic strategy for diabetes
Por: Mohammad Althubiti
Publicado em: (2022-01-01)

Spleen tyrosine kinase inhibitors disrupt human neutrophil swarming and antifungal functions
Por: Alex Hopke, et al.
Publicado em: (2025-01-01)

Stress Granules Modulate SYK to Cause Microglial Cell Dysfunction in Alzheimer's Disease
Por: Soumitra Ghosh, et al.
Publicado em: (2015-11-01)

Fluorescent Tracking of Yeast Division Clarifies the Essential Role of Spleen Tyrosine Kinase in the Intracellular Control of Candida glabrata in Macrophages
Por: Zeina Dagher, et al.
Publicado em: (2018-05-01)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
Por: Chen-Yu Hu, et al.
Publicado em: (2019-12-01)

Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
Por: Xuejin Ou, et al.
Publicado em: (2024-09-01)

Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization
Por: Halil Ibrahim Onder, et al.
Publicado em: (2014-04-01)

Receptor Tyrosine Kinase Signaling Involves <i>Echinococcus</i>–Host Intercommunication: A Potential Therapeutic Target in Hepatic Echinococcosis
Por: Haijun Gao, et al.
Publicado em: (2024-08-01)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Por: Qinlian Jiao, et al.
Publicado em: (2018-02-01)

Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
Por: Sareshma Sudhesh Dev, et al.
Publicado em: (2021-11-01)

Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
Por: D. Samuel Metibemu, et al.
Publicado em: (2019-12-01)

Recent developments in receptor tyrosine kinases targeted anticancer therapy
Por: Samir H. Raval, et al.
Publicado em: (2016-01-01)

Complement receptor-3 negatively regulates the phagocytosis of degenerated myelin through tyrosine kinase Syk and cofilin
Por: Hadas Smadar, et al.
Publicado em: (2012-07-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
Por: Xu H, et al.
Publicado em: (2019-07-01)

Therapeutic potential of tyrosine-protein kinase MET in osteosarcoma
Por: Ming Zeng, et al.
Publicado em: (2024-03-01)